Huilai Zhang. "Novel triplet combination of orelabrutinib, lenalidomide, and rituximab as frontline therapy for mantle cell lymphoma: Final results of POLARIS multicenter phase II study.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.19_suppl.260